Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

npj Precision Oncology, an esteemed peer-reviewed journal published by NATURE PORTFOLIO, stands at the forefront of oncological research and precision medicine. Launched as an Open Access platform in 2017, this journal not only facilitates the dissemination of innovative research findings but also ensures that crucial insights are freely accessible to the global scientific community. With an impressive ranking of Q1 in both Cancer Research and Oncology, and a commendable Scopus rank that places it in the top 15% of its field, npj Precision Oncology is dedicated to advancing our understanding of personalized cancer therapies through high-quality research. Catering to professionals, researchers, and students alike, this journal aims to bridge the gap between laboratory science and clinical application, paving the way for transformative approaches in oncology. As the landscape of cancer treatment evolves, npj Precision Oncology remains a crucial platform for fostering collaboration and sparking ideas that can significantly impact patient care.

Discover Oncology, published by SPRINGER, is an influential journal based in Germany that focuses on the latest advancements in the fields of oncology and endocrinology. With an evolving scope that spans critical research from 2021 to 2024, this journal aims to provide a platform for innovative ideas and research findings that can significantly impact clinical practices. Although it currently holds a Q3 ranking in several Cancer Research and Endocrine category quartiles, its commitment to open access ensures that relevant knowledge is available to a wider audience, facilitating the exchange of ideas among researchers, professionals, and students. As evidenced by its growing presence in various medical spheres, including a Q2 ranking in Endocrinology and Diabetes, the journal plays a crucial role in advancing multidisciplinary research that integrates oncology with broader biological and medical parameters. For those in the field, Discover Oncology serves as both a resource and a community hub, encouraging collaboration and exploration of emerging findings that can lead to novel therapeutic approaches.

CELLULAR ONCOLOGY is an esteemed open access journal published by SPRINGER since 2004, specializing in the dynamic field of oncological research. With its ISSN 2211-3428 and E-ISSN 2211-3436, this journal plays a pivotal role in disseminating cutting-edge findings and innovative methodologies that address cancer at the cellular level. The journal has consistently achieved high-impact recognition, currently holding a Q2 rating in Cancer Research and Q1 rankings in Medicine (miscellaneous), Molecular Medicine, and Oncology as of 2023. Furthermore, it ranks 56th in oncology medicine and 48th in cancer research according to Scopus, placing it firmly within the top echelons of its field. Published in the Netherlands, with an aim to connect scientists, clinicians, and practitioners worldwide, CELLULAR ONCOLOGY fosters a collaborative environment for researchers to share insights, enhance understanding, and advance treatments. The journal’s open access model ensures that ground-breaking research is freely available, facilitating greater visibility and impact within the scientific community and beyond.

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.